LIXTE Biotechnology Appoints Sidney Braun to Lead European Proton Therapy Rollout
Sidney Braun, veteran healthcare executive, becomes CEO of LIXTE’s Liora Technologies Europe Ltd., overseeing rollout of its LiGHT System proton therapy platform. Braun’s appointment supports LIXTE’s plan to drive recurring revenue by scaling electronically controlled proton therapy for cancer treatment across Europe.
1. Appointment of Sidney Braun
LIXTE Biotechnology has appointed Sidney Braun as Chief Executive Officer of its wholly owned subsidiary, Liora Technologies Europe Ltd. Braun brings over two decades of operational and strategic advisory experience in healthcare across North America, Europe and Israel, including leading infusion and physician networks for major biologic therapies.
2. Strategic Expansion of LiGHT System
Under Braun’s leadership, Liora will advance commercialization of its proprietary LiGHT System, an electronically controlled proton therapy platform designed to improve tumor targeting in various cancers. This move aligns with LIXTE’s objective to establish a recurring revenue model by scaling proton therapy services throughout Europe.